Invesco Biotechnology & Genome ETF
PBE
73 hedge funds and large institutions have $53.9M invested in Invesco Biotechnology & Genome ETF in 2018 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 13 closing their positions.
1% more capital invested
Capital invested by funds: $53.2M → $53.9M (+$710K)
0.43% less ownership
Funds ownership: 22.09% → 21.67% (-0.43%)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
1% less funds holding
Funds holding: 74 → 73 (-1)
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.27M |
| 2 |
CWM
Cornerstone Wealth Management
St. Peters,
Missouri
|
+$995K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$582K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$449K |
| 5 |
OC
Oppenheimer & Co
New York
|
+$262K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.56M |
| 2 |
VF
Virtu Financial
New York
|
-$1.36M |
| 3 |
IFWM
Institute for Wealth Management
Denver,
Colorado
|
-$1.11M |
| 4 |
YIA
YHB Investment Advisors
West Hartford,
Connecticut
|
-$1M |
| 5 |
Morgan Stanley
New York
|
-$646K |
PBE Hedge Fund Activity: Q2 2018 in Review
73 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q2 2018, worth a combined $53.9M — up 1.3% from $53.2M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of PBE and 12 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 13 added.
The largest buyer was UBS Group, adding an estimated $1.27M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $1.56M sold.
- 73 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q2 2018, down from 74 in Q1 2018.
- Funds reported $53.9M of Invesco Biotechnology & Genome ETF stock for Q2 2018, up 1.3% quarter-over-quarter.
- 12 funds opened new Invesco Biotechnology & Genome ETF positions in Q2 2018 and 13 closed out, a net change of -1 holder.
- The largest Invesco Biotechnology & Genome ETF buyer in Q2 2018 was UBS Group, an estimated $1.27M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q2 2018 was Susquehanna International Group, an estimated $1.56M sold.
Based on aggregated 13F filings for Q2 2018.